Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health develops, manufactures and markets animal health products for farm animals and pets. News about ELAN commonly covers operating and financial results, product launches in pet health and livestock health, and regulatory actions involving animal medicines and parasite-control products.
Company updates also include capital-structure disclosures, investor conference presentations, and governance changes tied to Elanco's board and public-company operations. Product-specific developments have included the Advantage brand for dogs and emergency-authorized livestock treatments such as Negasunt Powder and Tanidil.
Elanco (NYSE: ELAN) launched Befrena (tirnovetmab), a new anti-IL-31 monoclonal antibody injection for canine allergic and atopic dermatitis in the $1.3 billion U.S. canine dermatology market. The phased U.S. launch begins via an Early Experience Program.
Befrena starts controlling itch within 24 hours, provides 6–8 weeks relief, has no age or weight restrictions, and is administered as an in-clinic injection. Approved by the USDA in December 2025, Befrena makes Elanco the only pet health company with two USDA-approved mAb products.
Elanco (NYSE: ELAN) announced management participation in two upcoming investor conferences. On May 27, 2026, CEO Jeff Simmons and CFO Bob VanHimbergen will join a fireside chat at the Stifel 2026 Jaws & Paws Conference. On June 2, 2026, Simmons will present at the William Blair 46th Annual Growth Stock Conference. Live audio webcasts and limited-time replays will be accessible in the Events and Presentations section of Elanco's investor website.
Elanco (NYSE: ELAN) reported Q1 2026 revenue of $1,371M (+15% reported, +10% organic CC). Adjusted EBITDA was $334M (24.5% margin); adjusted EPS was $0.40. Reported net income was $57M. The company raised full‑year 2026 guidance: revenue to $5,010–5,085M, adjusted EBITDA to $975–1,005M, adjusted EPS to $1.03–1.09, and improved year‑end net leverage target to 3.0x–3.2x.
Elanco (NYSE: ELAN) announced Emergency Use Authorization from the FDA for Negasunt Powder and an EPA Section 18 exemption for Tanidil to prevent and treat New World screwworm in multiple livestock species, effective April 27, 2026.
Both products will be distributed through APHIS and the National Veterinary Stockpile, used under coordination with state and tribal officials, and include strict safety, use, and withdrawal limitations.
Elanco (NYSE: ELAN) announced Emergency Use Authorization from the FDA for Negasunt Powder and a Section 18 EPA emergency exemption for Tanidil to prevent and treat New World screwworm infestations in multiple livestock species.
Products will be distributed through APHIS and the National Veterinary Stockpile; Tanidil exemption effective April 27, 2026 through April 27, 2029. Safety limits, PPE requirements, slaughter-withholding periods and use restrictions are included.
National Veterinary Associates (ACHC) named Todd S. Young as Chief Financial Officer, effective May 1, 2026. He will report to CEO John Bruno and join the executive leadership team. Young brings more than 25 years in human and animal healthcare finance, including prior CFO roles at Acadia Healthcare (NASDAQ: ACHC) and Elanco (NYSE: ELAN).
Young said he looks forward to strengthening NVA's financial foundation as the company continues investing across its care network.
Elanco (NYSE: ELAN) will announce its first quarter 2026 financial results on Wednesday, May 6, 2026 and will host a conference call the same day.
The conference call begins at 8:00 a.m. Eastern time, with a live webcast and subsequent replay accessible via the company investor website.
Elanco (NYSE: ELAN) launched the Advantage™ Collar for Dogs on April 9, 2026, offering four months of continuous protection against fleas, ticks and repelling mosquitoes* for dogs and puppies 12 weeks and older.
The adjustable, time-release collar strengthens Elanco's 25-year Advantage brand, will be sold at pet specialty, dollar, grocery and mass retailers, and has a suggested retail price below $25**. Excludes California for the mosquito claim.
Elanco (NYSE: ELAN) reported Q4 2025 revenue of $1,144M (+12% reported, +9% organic CC) and full-year 2025 revenue of $4,715M (+6% reported, +7% organic CC). Innovation revenue exceeded target at $892M and 2026 innovation target raised to $1.15B. Reported net loss was $276M in Q4 and $232M for 2025; adjusted EBITDA was $189M Q4 and $901M FY. Full-year 2026 guidance: revenue $4,950–$5,020M, adjusted EBITDA $955–$985M, adjusted EPS $1.00–$1.06, and year-end net leverage target 3.1x–3.3x.
Elanco (NYSE: ELAN) announced management participation in multiple investor conferences between Feb 26 and Mar 17, 2026. Executives including Jeff Simmons, Bob VanHimbergen, Luke Smith and Bobby Modi will appear in scheduled fireside chats with banks and healthcare conferences.
Live audio webcasts will be available in the Events and Presentations section of Elanco's investor website; replays will be posted for a limited time after each event.